As of now, there is no cure for the deadly coronavirus that has spread fear all over the world since December 2019.
In the meantime, a new study showed that Gilead Sciences (GILD) - Get Report experimental drug, remdesivir, has successfully prevented the Middle East respiratory syndrome coronavirus (MERS-CoV) disease in monkeys.
The results, which appeared in the Proceedings of the National Academy of Sciences, also found that remdesivir also reduced the severity of symptoms in monkeys infected by MERS-CoV.
MERS-CoV is closely related to the deadly 2019 novel coronavirus (2019-nCoV), which is why researchers are hopeful that this might lead somewhere.
On February 26, the drugmaker, Gilead Sciences, announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with novel coronavirus.
But it's also worth-noting that the remdesivir had been found to effectively treat monkeys infected with Ebola virus, but not with humans.
The new coronavirus, has killed at least 2,700 people and infected more than 80,000 worldwide.
Catch up on the Latest Videos on TheStreet!
- Coronavirus Explained: Here's What You Need to Know
- Jim Cramer: You Can't Invest Based on the Number of Coronavirus Infections
- Valentine's Day 2020: Expect Record Spending
- Jim Cramer Puts Tom Brady, Ryan Tannehill and Philip Rivers Against Stocks
- Jeff Bezos Purchases Warner Estate From David Geffen For $165 Million
- TheStreet Explains: How to Find a Good Savings Account
- Retirement Daily: Got Gigs? Get Smart About Your 1099-MISC Tax Form
- Free Webinar: Webinar - Expert Advice on FX/Metals Trading by CME Group